156 related articles for article (PubMed ID: 11148683)
41. Advances in pharmacotherapy for secondary hyperparathyroidism.
Rodríguez M; Rodríguez-Ortiz ME
Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
[TBL] [Abstract][Full Text] [Related]
42. Hungry bone syndrome.
Jain N; Reilly RF
Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):250-255. PubMed ID: 28375869
[TBL] [Abstract][Full Text] [Related]
43. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
44. [Therapy of hypercalcemia with ibandronate in case of acute renal failure].
Bergner R; Henrich DM; Hoffmann M; Bruckner D; Uppenkamp M
Internist (Berl); 2006 Mar; 47(3):293-6. PubMed ID: 16470360
[TBL] [Abstract][Full Text] [Related]
45. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism.
Marcocci C; Bollerslev J; Khan AA; Shoback DM
J Clin Endocrinol Metab; 2014 Oct; 99(10):3607-18. PubMed ID: 25162668
[TBL] [Abstract][Full Text] [Related]
46. Bone turnover markers in primary hyperparathyroidism.
Costa AG; Bilezikian JP
J Clin Densitom; 2013; 16(1):22-7. PubMed ID: 23374737
[TBL] [Abstract][Full Text] [Related]
47. Can biochemical abnormalities predict symptomatology in patients with primary hyperparathyroidism?
Bargren AE; Repplinger D; Chen H; Sippel RS
J Am Coll Surg; 2011 Sep; 213(3):410-4. PubMed ID: 21723154
[TBL] [Abstract][Full Text] [Related]
48. Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
LoCascio V; Braga V; Bertoldo F; Bettica P; Pasini AF; Stefani L; Moro L
Clin Endocrinol (Oxf); 1994 Jul; 41(1):47-51. PubMed ID: 8050131
[TBL] [Abstract][Full Text] [Related]
49. [New perspective in the medical management of primary hyperparathyroidism].
Wémeau JL; Fayard A
Ann Endocrinol (Paris); 2001 Nov; 62(5):454-7. PubMed ID: 11852353
[TBL] [Abstract][Full Text] [Related]
50. Medical approaches to primary hyperparathyroidism.
Strewler GJ
Endocrinol Metab Clin North Am; 2000 Sep; 29(3):523-39, vi. PubMed ID: 11033759
[TBL] [Abstract][Full Text] [Related]
51. Hyperparathyroidism of Renal Disease.
Yuen NK; Ananthakrishnan S; Campbell MJ
Perm J; 2016; 20(3):15-127. PubMed ID: 27479950
[TBL] [Abstract][Full Text] [Related]
52. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
53. Elevated serum parathyroid hormone concentration in eucalcemic patients after parathyroidectomy for primary hyperparathyroidism and its relationship to vitamin D profile.
Dhillon KS; Cohan P; Darwin C; Van Herle A; Chopra IJ
Metabolism; 2004 Sep; 53(9):1101-6. PubMed ID: 15334367
[TBL] [Abstract][Full Text] [Related]
54. New developments in the treatment of osteoporosis.
Eriksen EF; Halse J; Moen MH
Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
[TBL] [Abstract][Full Text] [Related]
55. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
56. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
57. Medical management of asymptomatic primary hyperparathyroidism.
Shane E
J Bone Miner Res; 1991 Oct; 6 Suppl 2():S131-4; discussion S151-2. PubMed ID: 1763664
[TBL] [Abstract][Full Text] [Related]
58. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Ważna-Jabłońska E; Gałązka Z; Durlik M
Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
[TBL] [Abstract][Full Text] [Related]
59. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism.
Ho LY; Wong PN; Sin HK; Wong YY; Lo KC; Chan SF; Lo MW; Lo KY; Mak SK; Wong AK
BMC Nephrol; 2017 Jan; 18(1):12. PubMed ID: 28073343
[TBL] [Abstract][Full Text] [Related]
60. Calcimimetic agents for the treatment of hyperparathyroidism.
Goodman WG
Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):575-80. PubMed ID: 11496049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
